Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Carcinoma

Carcinoma, Ovarian Epithelial

Adenocarcinoma, Clear Cell

Adenomyoepithelioma

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Ovarian Neoplasms

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Ovarian Cancer

Ovarian Epithelial Cancer

Epithelial-myoepithelial Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Immune Checkpoint Inhibitors

Antineoplastic Agents, Immunological

physician's choice of chemotherapy for relapsed/refractory ovarian clear cell carcinoma

physician's choice of chemotherapy

immune checkpoint inhibitor based therapy for relapsed/refractory ovarian clear cell carcinoma

immune checkpoint inhibitor based therapy

Qinglei Gao, PhD

The goal of this observational study is to learn about the treatment effectiveness of physician's choice of chemotherapy and the immune checkpoint inhibitor (ICI)-based therapy in patients with relapsed/refractory ovarian clear cell carcinoma (OCCC), and compare the treatment response with the phase II, single-arm clinical trial INOVA to investigate the efficacy of combinational therapy of sintilimab plus bevacizumab. The main questions it aims to answer are:

* What is the efficacy of physician's choice of chemotherapy in relapsed/refractory OCCC patients in the real world?
* Is ICI-based therapy more effective than physician's choice of chemotherapy in real-world for relapsed/refractory OCCC patients?
* Dose the combinational regimens of sintilimab plus bevacizumab in Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma (INOVA) trial more effective than physician's choice of chemotherapy?

Participants will be respectively retrieved and extracted de-identified, longitudinal electronic health records (EHR)-derived data.

A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary

The individual participant data will be available (including data dictionaries). The individual participant data that underlie the results reported in this article after deidentification (text, tables, figures, and appendices) in particular will be shared

The tumor responses to treatment were evaluated by an independent central investigator according to RECIST version 1.1

the time from therapy initiation to the first documented progression or death from any cause, whichever occurred first

the time from therapy initiation to the first documented complete response or partial response

the time from the first documented response to disease progression or death, whichever occurs first

the proportion of patients with complete response, partial response, and stable disease

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary	NCT06279104	Ovarian Clear C...	physician's cho... immune checkpoi...	18 Years - 75 Years	Tongji Hospital
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary	NCT06279104	Ovarian Clear C...	physician's cho... immune checkpoi...	18 Years - 75 Years	Tongji Hospital
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary	NCT06279104	Ovarian Clear C...	physician's cho... immune checkpoi...	18 Years - 75 Years	Tongji Hospital
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary	NCT06279104	Ovarian Clear C...	physician's cho... immune checkpoi...	18 Years - 75 Years	Tongji Hospital

Spots Global Cancer Trial Database for physician's choice of chemotherapy